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Objectives The aim of this study was to investigate the impact of reference vessel diameter (RVD) and lesion
length (LL) on the relative safety and efﬁcacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES).
Background Lesion length and RVD are well-known predictors of adverse events after percutaneous
coronary intervention.
Methods Patient-level data were pooled from the randomized SPIRIT (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) II, III, IV and COMPARE (Second-generation everolimus-eluting and
paclitaxel-eluting stents in real-life practice) trials. Quantitative angiographic core laboratory data were avail-
able for 6,183 patients randomized to EES (n  3,944) or PES (n  2,239). Long lesions and small vessels were
eﬁned as LL median (13.4 mm) and RVD median (2.65 mm), respectively. Major adverse cardiac events
MACE) (consisting of cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization)
ere assessed at 2 years, according to stent type in 3 groups: short lesions in large vessels (group A,
 1,297); long lesions or small vessels but not both (group B, n  2,981); and long lesions in small vessels
group C, n  1,905).
esults The pooled 2-year MACE rates were 5.6%, 8.2%, and 10.4% in Groups A, B, and C, respectively
p  0.0001). There was no signiﬁcant interaction between lesion group and stent type (p  0.64), indicating
ower MACE with EES compared with PES regardless of LL and RVD. However, the absolute difference was
argest in Groups B and C. In Group A, 2-year MACE rates were not signiﬁcantly different between EES and
ES (4.8% vs. 7.0%, respectively, p  0.11). In contrast, EES was associated with lower 2-year rates of MACE in
roup B (6.6% vs. 11.2%, p  0.01) and in Group C (9.1% vs. 12.7%, p  0.008) as well as lower rates of myo-
ardial infarction, target lesion revascularization, and stent thrombosis. Multivariable analysis conﬁrmed EES
ersus PES as an independent predictor of freedom from MACE in Groups B and C.
onclusions Patients with short lesions in large vessels have low rates of MACE at 2 years after treatment
ith either EES or PES. In higher-risk patients with long lesions and/or small vessels, EES results in signiﬁcant
mprovements in both clinical safety and efﬁcacy outcomes. (A Clinical Evaluation of the XIENCE V Everolimus
luting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions;
CT00180310; SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coro-
ary Stent System [EECSS] in the Treatment of Subjects With de Novo Native Coronary Artery Lesions;
CT00180479; SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
ystem in the Treatment of Subjects With de Novo Native Coronary Artery Lesions; NCT00307047; A Random-
zed Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in
aily Practice: The COMPARE Trial; NCT01016041) (J Am Coll Cardiol Intv 2011;4:1209–15) © 2011 by the
merican College of Cardiology Foundation
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1210First-generation drug-eluting stents (DES), introduced nearly
10 years ago, resulted in a substantial reduction in angiographic
restenosis and the need for repeat revascularization procedures
compared with bare-metal stents (BMS) (1,2). Nonetheless,
restenosis still occurs after DES, and first-generation DES
have been associated with increased rates of very late (1 year)
tent thrombosis compared with BMS (1,3). A new generation
f DES has been designed with the aim to further enhance
afety and efficacy in patients undergoing percutaneous coronary
See page 1216
intervention (PCI). The XIENCE V everolimus-eluting
stent (EES) (Abbott Vascular, Santa Clara, California; also
distributed as PROMUS, Boston Scientific, Natick, Mas-
sachusetts) is a second-generation DES that has been
compared with the TAXUS paclitaxel-eluting stent (PES)
(Boston Scientific) in the random-
ized SPIRIT (Clinical Evaluation
of the XIENCE V Everolimus
Eluting Coronary Stent System)
II, SPIRIT III, SPIRIT IV, and
COMPARE (Second-generation
everolimus-eluting and paclitaxel-
eluting stents in real-life practice)
trials. A recent meta-analysis of
these 4 trials showed a significant
reduction in target lesion revascular-
ization (TLR), myocardial infarc-
tion (MI), and stent thrombosis at
1-year follow-up with EES com-
pared with PES (4).
Greater lesion length (LL)
and smaller reference vessel di-
ameter (RVD) are 2 of the 3
main risk factors for restenosis
after PCI (5–11), the third being
diabetes mellitus. However, the interaction between these
parameters and the relative safety and efficacy of first-
compared with second-generation DES has not been stud-
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accepted July 7, 2011.ied. Therefore, we evaluated the impact of LL and RVD on
the 2-year clinical outcomes after PCI with EES compared
with PES from a patient-level pooled analysis from the
SPIRIT and COMPARE randomized trials.
Methods
Study description. For the present analysis, the databases
from the 4 prospective, single-blind, randomized trials of EES
versus PES were pooled for a patient level analysis. These trials
included the SPIRIT II, SPIRIT III, and SPIRIT IV trials
(12–14), in which patients with noncomplex de novo coronary
artery lesions were randomized to treatment with the Xience V
EES or the Taxus Express PES, and the COMPARE trial
(15), in which an unselected cohort of consecutive patients
with coronary artery disease were randomized to treatment
with the Xience V EES or the Taxus Liberté PES. Details of
study design, conduct of the trials, and primary study results
have been published previously (12–16). A total of 6,789
patients with 8,823 treated lesions were included in the 4 trials.
Baseline core laboratory-assessed quantitative coronary angiog-
raphy data on LL and RVD were complete and available for
6,183 patients (91.1%) with 7,716 lesions (87.5%), who con-
stitute the study cohort for the current analysis.
Deﬁnitions and clinical endpoints. Follow-up in all 4 included
trials is presently complete to at least 2 years, with annual
follow-up continuing to 5 years. Endpoints included major ad-
verse cardiac events (MACE) (a composite of cardiac death, MI,
or ischemia-driven target lesion revascularization [ID-TLR]),
death (cardiac and noncardiac), MI, ID-TLR, and stent throm-
bosis according to the Academic Research Consortium definite or
probable criteria (17). Data from the original databases, as defined
and adjudicated by the clinical events committees for each study,
were used in our analysis. Common definitions of endpoints were
used in all 4 trials (12–16).
Statistical analysis. Categorical variables were compared with
he chi-square test or Fisher exact test. Continuous variables
re described as mean  SD and were compared by means of
tudent t test. To eliminate bias, long lesions and small vessels
ere defined as LL greater than the median and RVD less
han or equal to the median, respectively. Two-year outcomes
ccording to stent type were examined after PCI in short
esions in large vessels (Group A), in either long lesions in large
essels or short lesions in small vessels (Group B), and in long
esions in small vessels (Group C). Longitudinal results are
isplayed as time-to-event curves, and Kaplan-Meier estimates
f event rates were compared by the log-rank test. We included
ata from all patients analyzed in each of the original study
eports in our analysis, with follow-up data censored at the
ime of first event or latest known follow-up. To investigate the
mpact of EES versus PES randomization on the occurrence of
he 2-year rate of MACE according to LL and RVD, stepwise
ox proportional hazards regression analysis was performed inach group with stent randomization type forced into the
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1211model. Interaction tests were performed by including the cross
product of 2 variables (an interaction term) in the Cox model.
In order not to overfit the model, a limited number of
covariates that by chance were imbalanced between the stent
types and other variables known to affect MACE were intro-
duced into the model, including: acute coronary syndrome,
diabetes mellitus, hypertension, hypercholesterolemia, treat-
ment of any lesion with thrombus, treatment of any lesion with
moderate or severe calcification, treatment of any lesion with
baseline Thrombolysis In Myocardial Infarction flow grade 0
or 1, LL (in case of multiple lesions, the longest lesion was
selected), RVD (in case of multiple lesions, the smallest RVD
was selected), and randomization to EES versus PES.
Results
The median LL was 13.4 mm (interquartile range: 10.0 to 19.4
mm), and the median RVD was 2.65 mm (interquartile range:
2.31 to 3.01 mm). Thus, patients were divided into 3 increasingly
complex groups: Group A, LL13.4 mm and RVD2.65 mm
n  1,297, 21.0%); Group B, LL 13.4 mm or RVD 2.65
m but not both (n 2,981, 48.2%); and Group C, LL13.4
m and RVD 2.65 mm (n  1,905, 30.8%). The proportion
f patients randomized in the all-comers COMPARE trial
ncreased with lesion complexity (Group A 13.0%, Group B
8.1%, Group C 27.4%, p for trend 0.01).
The baseline demographic and angiographic characteristics
tratified according to the 3 groups appear in Table 1. Patients
andomized to EES compared with PES in Groups A and B less
ften had acute coronary syndromes as the indication for their
ndex procedure. Moreover, patients randomized to EES in group
more often had hypercholesterolemia; those in group B less
ften had intracoronary thrombus, moderate or severe calcifica-
ions, and a baseline Thrombolysis In Myocardial Infarction flow
rade 0 or 1; and those in group C more often had hypertension,
ypercholesterolemia, and moderate or severe calcifications com-
ared with patients randomized to the PES. The LL was also
omewhat shorter in group C in patients randomized to EES
ompared with PES. There were no significant differences in
lopidogrel usage between patients randomized to ESS compared
ith PES at discharge (Group A 96.9% vs. 96.1%, p  0.53,
roup B 97.0% vs. 97.2%, p 0.82, Group C 97.6% vs. 97.4%,
 0.88) and at 1 year (Group A 76.2% vs. 77.1%, p  0.74,
roup B 79.5% vs. 78.1%, p 0.37, Group C 79.9% vs. 80.2%,
 0.91).
Table 2 shows procedural results and angiographic out-
omes. In Group A, there were no significant differences in
cute outcomes between patients randomized to EES versus
ES. In Group B, the post-procedural in-segment diameter
tenosis was slightly lower in the EES arm (14.8% vs.
5.6%, p  0.01). In Group C, the total stent length (41.6
m vs. 45.0 mm, p  0.01) was less in the EES arm,oncordant with the longer mean lesion length in the PESrm. Other slight post-procedural angiographic differences
etween EES and PES in Group C were present.
Clinical outcomes. The overall pooled 2-year MACE rates
ere lowest in Group A, intermediate in Group B, and
ighest in Group C (5.6% vs. 8.2% vs. 10.4%, p  0.0001).
ithin Group B, 2-year clinical outcome was similar in
atients with long lesions in large vessels and patients with
hort lesions in small vessels, with the exception of a higher
D-TLR rate in patients with short lesions in small vessels
4.0% vs. 6.1%, p  0.01). Table 3 shows the components
of MACE and stent thrombosis at 2-year follow-up in the
3 groups. Higher lesion complexity was also associated with
higher rates of MI (3.3% vs. 3.0% vs. 4.5%, p  0.02) and
ID-TLR (2.9% vs. 5.0% vs. 6.3%, p  0.0002).
Among patients treated with PES, as lesion complexity
increased from Group A to B to C, the 2-year rate of MACE
also increased (7.0% vs. 11.2% vs. 12.8%, respectively, p for
trend  0.007). The same relationship was noted among
atients treated with EES (4.8% vs. 6.6% vs. 9.1%, respec-
ively, p for trend  0.001). In contrast, although the 2-year
ate of definite or probable stent thrombosis also increased with
reater lesion complexity after PES implantation (0.7% vs. 1.9%
s. 2.8%, p for trend  0.03), a similar relationship for stent
hrombosis was not present after EES implantation (0.9%
s. 0.6% vs. 0.6%, p for trend  0.65).
The 2-year clinical outcomes according to stent type in each
roup appear in Figure 1 and Table 4. There was no significant
nteraction between lesion group and stent type (p  0.64),
ndicating lower 2-year MACE with EES compared with
ES, regardless of LL and RVD. However, the absolute
ifference was largest in Groups B and C. In Group A,
lthough the MACE rates were numerically less with EES
ompared with PES, the difference did not reach statistical
ignificance. In contrast, EES was associated with significantly
ower rates of MACE, MI, ID-TLR, and stent thrombosis in
roups B and C. Cardiac mortality was also significantly lower
n the EES arm in Group B (1.0% vs. 2.1%, p  0.03).
Multivariable analysis. Table 5 shows the predictors of
-year MACE in Groups A, B, and C. Use of EES rather
han PES was an independent predictor of freedom from
ACE in Group B (hazard ratio [HR]: 0.62, 95% confi-
ence interval [CI]: 0.49 to 0.79, p 0.0001) and Group C
HR: 0.67, 95% CI: 0.51 to 0.88, p  0.004) but not in
roup A (HR: 0.76, 95% CI: 0.50 to 1.15, p  0.19).
iscussion
The principal findings from this large patient-level pooled
analysis from 4 randomized trials in which EES and PES were
compared for the treatment of coronary artery disease are: 1)
2-year MACE rates in these contemporary DES trials were
highest in patients with long lesions in small vessels (10.4%),
intermediate in patients with either long lesions or small vessels
but not both (8.2%), and lowest in patients with short lesions in
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1212large vessels (5.6%); 2) MACE rates at 2 years were increased with
lesion complexity after treatment with EES and PES; however,
although the frequency of stent thrombosis increased steadily from
Group A to Group C after PES implantation, stent thrombosis
rates after EES were independent of lesion complexity; and 3)
there was no significant interaction between lesion group and stent
type on 2-year MACE, although absolute differences were great-
est in Groups B and C, resulting in significantly lower MACE
rates with EES in these patients with either long lesions and/or
small vessels.
Lesion length and RVD are known to be associated with
Table 1. Baseline Demographic and Angiographic Characteristics
Group A
LL <13.4 mm and RVD >2.65 mm
(n  1,297)
EES
(n  807,
NL  1,056)
PES
(n  490,
NL  632) p Value
Demographic data
Age (yrs) 63.4 10.8 63.2 10.6 0.76
Male 69.4% 72.4% 0.26
Diabetes mellitus 27.4% 27.6% 1.0
Insulin-treated 7.3% 7.8% 0.83
Hypertension 73.4% 69.4% 0.13
Hypercholesterolemia 73.6% 68.1% 0.04
Current smoker 21.7% 22.2% 0.89
Prior PCI 17.0% 13.1% 0.07
Prior CABG 7.7% 3.9% 0.01
Prior MI 20.7% 18.1% 0.28
Acute coronary syndrome 25.5% 33.3% 0.01
Unstable angina 21.4% 26.5% 0.047
NSTEMI 2.5% 3.7% 0.23
STEMI 2.0% 3.7% 0.07
Lesion characteristics
Coronary artery location
Left main 0.2% 0.7% 0.21
Left anterior descending 38.4% 39.3% 0.74
Left circumﬂex 22.9% 22.8% 1.0
Right coronary artery 38.5% 37.1% 0.62
Saphenous vein graft 0.7% 0.7% 1.0
Presence of thrombus 4.4% 6.3% 0.13
Moderate/severe calciﬁcation 12.1% 10.2% 0.30
TIMI ﬂow grade 1 or 0 2.8% 3.4% 0.45
ACC/AHA class B2/C lesions 43.3% 42.3% 0.76
Lesion length (mm) 10.06 2.33 9.94 2.27 0.30
Reference vessel diameter (mm) 3.07 0.34 3.09 0.35 0.14
Minimal lumen diameter (mm) 0.96 0.45 1.00 0.46 0.06
Diameter stenosis (%) 69.0 13.5 67.9 13.8 0.12
Values are mean SD or %.
ACC American College of Cardiology; AHA American Heart Association; CABG coronary art
NL number of lesions; NSTEMI non–ST-segment elevation myocardial infarction; PCI percut
ST-segment elevation myocardial infarction; TIMI Thrombolysis In Myocardial Infarction.adverse events after PCI (6–10,18). The present analysisdemonstrates that LL and RVD are still important corre-
lates of clinical outcomes even in the era of next-generation
DES. The relationship between RVD and restenosis has
been particularly well-described (6–9,19). Studies from the
BMS era demonstrated that the degree of late lumen loss
was relatively independent of coronary arterial diameter,
resulting in higher rates of binary angiographic restenosis
(and subsequent TLR) in small vessels (6). The same
relationship has been shown to hold true with first-
generation DES (11). Greater LL and/or use of longer
stents have also been associated with greater rates of
Group B
<2.65 mm and LL <13.4 mm or
D >2.65 mm and LL >13.4 mm
(n  2,981)
Group C
RVD <2.65 mm and LL >13.4 mm
(n  1,905)
ES
1,934,
2,379)
PES
(n  1,047,
NL  1,316) p Value
EES
(n  1,203,
NL  1,460)
PES
(n  702,
NL  873) p Value
 10.5 63.0 10.4 0.72 63.6 10.5 64.3 10.8 0.17
.2% 67.4% 0.68 67.8% 67.7% 0.96
.3% 28.1% 0.93 30.7% 27.7% 0.18
.9% 7.1% 0.88 9.0% 8.3% 0.67
.3% 69.6% 0.13 71.5% 65.5% 0.01
.4% 69.3% 0.23 72.3% 68.0% 0.047
.3% 27.5% 0.06 25.4% 22.1% 0.12
.4% 14.6% 0.91 13.8% 12.9% 0.62
.8% 6.5% 0.82 8.3% 6.1% 0.09
.0% 18.7% 0.44 21.8% 20.5% 0.52
.7% 37.1% 0.01 34.4% 35.5% 0.65
.1% 24.2% 0.01 25.5% 21.9% 0.08
.9% 7.5% 0.01 4.2% 4.3% 1.0
.0% 5.7% 0.01 5.0% 9.4% 0.01
.1% 0.5% 0.08 0.6% 0.4% 0.78
.7% 41.0% 0.68 39.9% 39.5% 0.85
.2% 24.9% 0.63 27.7% 29.2% 0.37
.0% 33.7% 0.86 31.8% 30.8% 0.59
.3% 0.6% 0.29 0.6% 0.3% 0.27
.0% 8.1% 0.01 4.8% 5.9% 0.20
.1% 14.8% 0.02 15.1% 21.1% 0.01
.3% 4.8% 0.03 5.5% 5.7% 0.76
.9% 53.7% 0.92 64.8% 65.4% 0.98
 9.15 16.24 11.31 0.22 22.91 10.58 25.34 13.05 0.01
 0.50 2.765 0.55 0.28 2.25 0.28 2.25 0.28 0.87
 0.40 0.85 0.40 0.13 0.71 0.36 0.76 0.39 0.01
 13.7 68.6 13.6 0.12 69.5 14.2 67.6 15.4 0.01
ass graft surgery; EES everolimus-eluting stent(s); LL lesion length; MImyocardial infarction;
coronary intervention; PES paclitaxel-eluting stent(s); RVD reference vessel disease; STEMIRVD
RV
E
(n 
NL 
62.8
68
28
6
72
71
24
14
6
20
29
24
2
3
0
41
24
34
0
5
12
3
53
15.79
2.67
0.83
69.3
ery byp
aneousrestenosis with both BMS and DES (9,10,18). Longer
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1213lesions require treatment with longer balloons and stents,
leading to greater arterial injury, which might result in
exaggerated neointimal hyperplasia.
Although prior studies have shown greater freedom from
MACE with the second-generation EES compared with the
first-generation PES, clinical and angiographic restenosis rates are
still increased after EES in small vessels and long lesions (11,12).
In the present study, the 2-year rates of MACE with both EES
and PES were greatest in long lesions in small vessels, interme-
diate in long lesions or in small vessels, and lowest when implanted
in short lesions in large vessels. Of interest, however, is that
although the 2-year rate of both definite and definite or probable
stent thrombosis increased in smaller vessels and/or longer lesions
with PES, a similar relationship was not seen with EES. This
Table 3. 2-Year Outcomes According to Vessel Diameter and Lesion Lengt
Group A
LL <13.4 mm and RVD >2.65 mm
(n  1,297)
R
R
Major adverse cardiac events 5.6%
Death 2.7%
Cardiac death 0.6%
Myocardial infarction 3.3%
ID target lesion revascularization 2.9%
Deﬁnite or probable stent thrombosis 0.8%
Deﬁnite stent thrombosis 0.5%
Table 2. Procedural Characteristics and Post-Procedural Angiographic Res
Group A
LL <13.4 mm and RVD >2.65 mm
(n  1,297)
EES
(n  807,
NL  1,056)
PES
(n  490,
NL  632) p Value
Procedural characteristics
Stents/patient 1.2 0.5 1.2 0.6 0.19
Stents/lesion 1.1 0.3 1.1 0.3 0.36
Stent length/patient (mm) 20.2 9.5 20.4 12.2 0.79
Stent length/lesion (mm) 18.6 6.0 18.4 8.9 0.36
Post-procedural angiographic results
Minimal luminal diameter (mm)
In-stent 2.98 0.37 3.01 0.34 0.11
In-segment 2.62 0.39 2.61 0.41 0.77
Diameter stenosis (%)
In-stent 1.9 8.0 1.3 8.9 0.21
In-segment 13.9 7.0 14.5 7.8 0.16
Acute gain (mm)
In-stent 2.05 0.53 2.06 0.49 0.62
In-segment 1.67 0.54 1.62 0.55 0.07
Values are mean SD.
Abbreviations as in Table 1.ID ischemia-driven; other abbreviations as in Table 1.relative freedom from stent thrombosis with EES in complex
lesions might underlie much of the benefit of EES in reducing
thrombotic events compared with PES, as found in the random-
ized trials (11–14). The low stent thrombosis rate with EES in
complex lesions in the present study might in part be attributable
to the relatively thin (8 m) nonthrombogenic fluoropolymer on
the surface of the EES (20). In contrast, PES is coated with a
thicker (17.8m) 3-layer styrene-isobutylene-styrene polymer. In
vitro studies have also demonstrated pro-thrombotic effects asso-
ciated with PES, including up-regulation of tissue factor and
plasminogen activator inhibitor-1 (21,22). Moreover, EES has
shown significantly faster re-endothelialization at 14 days after
stent implantation in a rabbit iliac artery model compared with
PES (23).
Group B
.65 mm and LL <13.4 mm or
2.65 mm and LL >13.4 mm
(n  2,981)
Group C
RVD <2.65 mm and LL >13.4 mm
(n  1,905) p Value
8.2% 10.4% 0.0001
2.6% 2.1% 0.50
1.4% 1.1% 0.13
3.0% 4.5% 0.02
5.0% 6.3% 0.0002
1.1% 1.4% 0.25
0.8% 0.9% 0.37
Group B
VD <2.65 mm and LL <13.4 mm or
RVD >2.65 mm and LL >13.4 mm
(n  2,981)
Group C
RVD <2.65 mm and LL >13.4 mm
(n  1,905)
EES
1,934,
2,379)
PES
(n  1,047,
NL  1,316) p Value
EES
(n  1,203,
NL  1,460)
PES
(n  702,
NL  873) p Value
 0.9 1.5 0.9 0.89 2.1 1.2 2.2 1.3 0.07
 0.5 1.2 0.5 0.14 1.4 0.5 1.4 0.6 0.02
 17.3 28.8 19.1 0.83 41.6 23.1 45.0 29.4 0.01
 10.7 23.0 11.9 0.12 28.5 13.1 28.9 18.8 0.53
 0.48 2.75 0.48 0.85 2.44 0.35 2.49 0.34 0.01
 0.47 2.31 0.50 0.38 2.10 0.38 2.09 0.40 0.82
 8.9 1.3 8.4 0.51 2.3 8.4 1.3 9.4 0.03
 8.0 15.6 9.0 0.01 15.9 8.3 15.9 8.8 0.88
 0.50 1.90 0.48 0.93 1.79 0.43 1.85 0.44 0.01
 0.54 1.46 0.56 0.06 1.38 0.49 1.33 0.55 0.02h
VD <2
VD >ults
R
(n 
NL 
1.5
1.2
29.0
23.6
2.76
2.32
1.5
14.8
1.90
1.50
s
r
p
CI  c
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1214The present analysis confirms and extends previous obser-
vations regarding the relative safety and efficacy of EES
compared with PES (4,12–15,24). We observed a significant
reduction in 2-year MACE with EES in patients with either
long lesions, small vessels, or both, indicating that the benefits
of the EES relative to the PES are more pronounced in these
more complex lesions. These results were confirmed by mul-
tivariable Cox regression analysis. The differences in 2-year
MACE were mainly driven by lower MI and ID-TLR rates in
the EES arms, although cardiac mortality was also significantly
reduced in Group B with EES (1.0% vs. 2.1%, p  0.03). In
contrast, the 2-year rates of MACE were not significantly
reduced with EES compared with PES in the low-risk Group
A (short lesions in large vessels), although a numerical trend
was present favoring EES (4.8% vs. 7.0%, p  0.11). A larger
tudy than even the current pooled analysis of these 4 trials is
equired to determine whether EES offers an advantage com-
ared with PES in such lesions.
Study limitations. Several limitations of our analysis deserve
comment. This study is a patient-level pooled analysis of 4
randomized clinical trials using different inclusion and
Figure 1. Time-to-Event Curves of MACE
Time-to-event curves of major adverse cardiac events (MACE) in patients rando
according to lesion length and reference vessel diameter. See text for details.
Table 4. 2-Year Outcomes With EES Versus PES According to Vessel Diam
Group A
LL <13.4 mm and RVD >2.65 mm
(n  1,297)
EES
(n  807)
PES
(n  490) p Value
Major adverse cardiac events 4.8% 7.0% 0.11
Death 2.7% 2.8% 0.93
Cardiac death 0.8% 0.4% 0.47
Myocardial infarction 2.7% 4.3% 0.14
ID target lesion revascularization 4.3% 5.5% 0.37
Deﬁnite or probable stent thrombosis 0.9% 0.7% 0.62
Deﬁnite stent thrombosis 0.6% 0.2% 0.29Abbreviations as in Tables 1 and 3.exclusion criteria, clinical sites, core laboratories, and end-
point adjudication committees. Although the SPIRIT trials
randomized noncomplex patients and lesions, COMPARE
was a real world “all-comers” trial. Notwithstanding these
differences in trial design, the results from these 4 individual
trials were consistent. The PES tested was the TAXUS
Liberté in the COMPARE trial and the TAXUS Express
(Boston Scientific) in the SPIRIT trials. However, no major
differences have been reported between the 2 versions of the
stent (25), although it has been suggested that the Liberté
platform might be superior in small vessels and long lesions
(26). Randomization was not stratified according to LL or
RVD, and small baseline clinical and angiographic differ-
ences between patients treated with EES and PES were
present in the 3 groups. However, EES remained superior
to PES in terms of 2-year MACE in Groups B and C after
multivariable analysis after adjusting for these differences.
Quantitative coronary angiography was performed by 2
different core laboratories (SPIRIT II, COMPARE: Car-
dialysis, Rotterdam, the Netherlands; SPIRIT III, SPIRIT
IV, Cardiovascular Research Foundation, New York, New
to everolimus-eluting stents (EES) versus paclitaxel-eluting stents (PES)
onﬁdence interval; HR  hazard ratio.
nd LL
Group B
D <2.65 mm and LL <13.4 mm or
VD >2.65 mm and LL >13.4 mm
(n  2,981)
Group C
RVD <2.65 mm and LL >13.4 mm
(n  1,905)
ES
1,934)
PES
(n  1,047) p Value
EES
(n  1,203)
PES
(n  702) p Value
.6% 11.2% 0.0001 9.1% 12.7% 0.008
.2% 3.3% 0.13 2.1% 2.0% 0.90
.0% 2.1% 0.03 1.3% 0.7% 0.27
.3% 4.3% 0.003 3.3% 6.7% 0.0008
.9% 7.2% 0.0001 5.5% 7.6% 0.04
.6% 1.9% 0.001 0.6% 2.8% 0.0001
.5% 1.4% 0.005 0.3% 1.9% 0.0007mizedeter a
RV
R
E
(n 
6
2
1
2
3
0
0
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1215York), and there are no data available with regard to intra-
and interobserver variability.
Conclusions
Our study examined the impact of LL and RVD on 2-year
clinical outcomes after PCI with EES compared with PES in
a pooled, patient-level analysis from 4 randomized controlled
trials. Two-year MACE rates increased with both stents with
greater LL and smaller RVD, although stent thrombosis rates
after EES were independent of lesion complexity. Use of EES
was associated with reduced 2-year rates of MACE, MI,
ID-TLR, and stent thrombosis in patients with long lesions
and/or small vessels.
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